27 products total (w/ the additional products distributed in Mexico). Big Pharma is looking @ the IPs . - the patents , and maybe a future publication in a journal that the oncology community reads. it requires patience on a different level for shareholders , as the community hurdle is there also. We are in that waiting period longs . i hope you all will understand the hurdles in Bio-Tech . We're not @ level 1.0 SEC filings current , or 2.0 clinical trials and FDA approval, but we are @ 3.0 , and now waiting on approval by the oncology community . These are the people that decide which treatments get used - along with the insurers . NanoStilbene could lower the overall insurance cost if used in combination w/ chemotherapy, radiotherapy, and various immunotherapies .
August 26, 2019 TSOI) announced today positive results from a pilot clinical trial in advanced cancer patients which have been submitted as a scientific manuscript to a peer reviewed medical journal.
it will get very interesting from here on out ;) publication & cred from the R and D side of TSOI IMO